Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): Rationale and design

Stefano Ghio, Diana Bonderman, Stephan B. Felix, Hossein A. Ghofrani, Evangelos D. Michelakis, Veselin Mitrovic, Ronald J. Oudiz, Reiner Frey, Lothar Roessig, Marc J. Semigran

Research output: Contribution to journalArticlepeer-review

Abstract

Aims Pulmonary hypertension (PH) due to systolic left ventricular dysfunction (PH-sLVD) frequently complicates heart failure (HF), and greatly worsens the prognosis of patients with sLVD, but as yet has no approved treatment. The LEPHT study Aims to characterize the haemodynamic profile, safety, tolerability, and pharmacokinetic profile of riociguat (BAY 63-2521), an oral stimulator of soluble guanylate cyclase, in patients with PH-sLVD.Methods and resultsThis 16-week, phase IIb, randomized, placebo-controlled, double-blind study enrols patients with PH-sLVD, defined as left ventricular ejection fraction (LVEF) ≤40 and mean pulmonary arterial pressure (PAPmean)

Original languageEnglish
Pages (from-to)946-953
Number of pages8
JournalEuropean Journal of Heart Failure
Volume14
Issue number8
DOIs
Publication statusPublished - Aug 2012

Keywords

  • Clinical trial
  • Pulmonary hypertension
  • Riociguat
  • Soluble guanylate cyclase stimulator
  • Systolic heart failure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): Rationale and design'. Together they form a unique fingerprint.

Cite this